vs
DYNEX CAPITAL INC（DX）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
DYNEX CAPITAL INC的季度营收约是ARS Pharmaceuticals, Inc.的1.5倍（$43.5M vs $28.1M），DYNEX CAPITAL INC同比增速更快（531.3% vs -67.6%）
Dynex Capital Inc是一家总部位于美国的上市房地产投资信托公司，专注于投资和管理抵押贷款支持证券、住宅及商业抵押贷款等各类抵押相关资产组合，通过稳健运营为股东创造稳定分红和长期资本增值。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
DX vs SPRY — 直观对比
营收规模更大
DX
是对方的1.5倍
$28.1M
营收增速更快
DX
高出598.9%
-67.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.5M | $28.1M |
| 净利润 | — | $-41.3M |
| 毛利率 | — | — |
| 营业利润率 | — | -147.6% |
| 净利率 | — | -147.1% |
| 营收同比 | 531.3% | -67.6% |
| 净利润同比 | — | -182.8% |
| 每股收益（稀释后） | $1.59 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXSPRY
| Q4 25 | $43.5M | $28.1M | ||
| Q3 25 | $30.6M | $32.5M | ||
| Q2 25 | $23.1M | $15.7M | ||
| Q1 25 | $17.1M | $8.0M | ||
| Q4 24 | — | $86.6M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $500.0K | ||
| Q1 24 | $-3.2M | $0 |
净利润DXSPRY
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $150.4M | $-51.2M | ||
| Q2 25 | $-13.6M | $-44.9M | ||
| Q1 25 | $-3.1M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | — | $-19.1M | ||
| Q2 24 | — | $-12.5M | ||
| Q1 24 | $40.1M | $-10.3M |
营业利润率DXSPRY
| Q4 25 | — | -147.6% | ||
| Q3 25 | — | -163.7% | ||
| Q2 25 | — | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | — | -3068.0% | ||
| Q1 24 | — | — |
净利率DXSPRY
| Q4 25 | — | -147.1% | ||
| Q3 25 | 491.3% | -157.4% | ||
| Q2 25 | -58.8% | -285.6% | ||
| Q1 25 | -18.0% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | — | -925.0% | ||
| Q2 24 | — | -2503.2% | ||
| Q1 24 | -1256.8% | — |
每股收益（稀释后）DXSPRY
| Q4 25 | $1.59 | $-0.41 | ||
| Q3 25 | $1.08 | $-0.52 | ||
| Q2 25 | $-0.14 | $-0.46 | ||
| Q1 25 | $-0.06 | $-0.35 | ||
| Q4 24 | — | $0.52 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | $0.64 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $531.0M | $245.0M |
| 总债务越低越好 | — | $96.4M |
| 股东权益账面价值 | $2.5B | $114.3M |
| 总资产 | $17.3B | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资DXSPRY
| Q4 25 | $531.0M | $245.0M | ||
| Q3 25 | $491.0M | $288.2M | ||
| Q2 25 | $387.5M | $240.1M | ||
| Q1 25 | $327.4M | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | $295.7M | $223.6M |
总债务DXSPRY
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DXSPRY
| Q4 25 | $2.5B | $114.3M | ||
| Q3 25 | $2.0B | $147.7M | ||
| Q2 25 | $1.6B | $192.3M | ||
| Q1 25 | $1.4B | $229.0M | ||
| Q4 24 | — | $256.8M | ||
| Q3 24 | — | $201.0M | ||
| Q2 24 | — | $215.2M | ||
| Q1 24 | $958.5M | $223.9M |
总资产DXSPRY
| Q4 25 | $17.3B | $327.7M | ||
| Q3 25 | $14.2B | $372.8M | ||
| Q2 25 | $11.3B | $313.5M | ||
| Q1 25 | $9.0B | $327.3M | ||
| Q4 24 | — | $351.2M | ||
| Q3 24 | — | $217.6M | ||
| Q2 24 | — | $222.0M | ||
| Q1 24 | $6.3B | $227.6M |
负债/权益比DXSPRY
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $120.8M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DXSPRY
| Q4 25 | $120.8M | $-43.5M | ||
| Q3 25 | $68.3M | $-47.0M | ||
| Q2 25 | $31.9M | $-39.6M | ||
| Q1 25 | $6.4M | $-40.7M | ||
| Q4 24 | — | $42.0M | ||
| Q3 24 | — | $-14.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | $-17.1M | $-6.7M |
自由现金流DXSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
自由现金流率DXSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
资本支出强度DXSPRY
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
现金转化率DXSPRY
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DX
暂无分部数据
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
